Otonomy looking beyond Meniere disease after latest Phase III miss

Otonomy will look ahead to a pipeline addressing tinnitus and hearing loss after its latest Phase III failure in Meniere disease. 

With Monday’s readout, Otonomy Inc. (NASDAQ:OTIC) shares fell $2.39 (44%) to $3.00, cutting the company’s market cap down to about $145 million...